Integrins and p53 pathways in glioblastoma resistance to temozolomide
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Glioblastoma is the most common malignant primary brain tumor. Surgical resection, postoperative radiotherapy plus concomitant and adjuvant chemotherapy with temozolomide (TMZ) is the standard of care for newly diagnosed glioblastoma. In the past decade, efforts have been made to decipher genomic and core pathway alterations to identify clinically relevant glioblastoma subtypes. Based on these studies and more academic explorations, new potential therapeutic targets were found and several targeting agents were developed. Such molecules should hopefully overcome the resistance of glioblastoma to the current therapy. One of the hallmarks of glioblastoma subtypes was the enrichment of extracellular matrix/invasion-related genes. Integrins, which are cell adhesion molecules important in glioma cell migration/invasion and angiogenesis were one of those genes. Integrins seem to be pertinent therapeutic targets and antagonists recently reached the clinic. Although the p53 pathway appears often altered in glioblastoma, conflicting results can be found in the literature about the clinically relevant impact of the p53 status in the resistance to TMZ. Here, we will summarize the current knowledge on (1) integrin expression, (2) p53 status, and (3) relationship between integrins and p53 to discuss their potential impact on the resistance of glioblastoma to temozolomide.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The first 30 years of p53: growing ever more complex.
Levine, A. J., & Oren, M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2723 · Cited by 1,967 · cited 3×
“Hazem J. Abuhusain, University of New South Wales, Australia Leonora Balaj, Massachusetts General Hospital, USA Brenda Auffinger, University of Chicago, USA *Correspondence: Monique Dontenwill, Laboratory of Biophotonics and Pharmacology, UMR 7213 CNRS, Faculté de Pharmacie, Université de Strasbourg, 74 Route du Rhin,…”
BackgroundIntegrins in angiogenesis and lymphangiogenesis
Avraamides, C. J., Garmy-Susini, B., & Varner, J. A. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2353 · Cited by 1,050
p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation
Zheng, H., Ying, H., Yan, H., Kimmelman, A. C., Hiller, D. J., Chen, A.-J., Perry, S. R., Tonon, G., Chu, G. C., Ding, Z., et al. (2008) · Nature · doi:10.1038/nature07443 · Cited by 767 · cited 4×
“An elegant study showed that dual inactivation of p53 and PTEN in murine NSC promotes an undifferentiated state with high renewal potential and generates tumors with a high grade glioma phenotype (Zheng et al., 2008).”
BackgroundInfluentialApoptosis of adherent cells by recruitment of caspase-8 to unligated integrins
Stupack, D. G., Puente, X. S., Boutsaboualoy, S., Storgard, C. M., & Cheresh, D. A. (2001) · The Journal of Cell Biology · doi:10.1083/jcb.200106070 · Cited by 554
Gene expression profiling and genetic markers in glioblastoma survival
Rich, J. N., Hans, C., Jones, B., Iversen, E. S., McLendon, R. E., Rasheed, B. K. A., Dobra, A., Dressman, H. K., Bigner, D. D., Nevins, J. R., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3936 · Cited by 316
An integrin αvβ3–c-Src oncogenic unit promotes anchorage-independence and tumor progression
Desgrosellier, J. S., Barnes, L. A., Shields, D. J., Huang, M., Lau, S. K., Prévost, N., Tarin, D., Shattil, S. J., & Cheresh, D. A. (2009) · Nature Medicine · doi:10.1038/nm.2009 · Cited by 293
Direct In Vivo Evidence for Tumor Propagation by Glioblastoma Cancer Stem Cells
Lathia, J. D., Gallagher, J., Myers, J. T., Li, M., Vasanji, A., McLendon, R. E., Hjelmeland, A. B., Huang, A. Y., & Rich, J. N. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024807 · Cited by 158
Fulci, G., Labuhn, M., Maier, D., Lachat, Y., Hausmann, O., Hegi, M. E., Janzer, R. C., Merlo, A., & Van Meir, E. G. (2000) · Oncogene · doi:10.1038/sj.onc.1203700 · Cited by 146 · cited 2×
“Prognostic and predictive markers are continuously proposed based on large scale genomic data.”
BackgroundMethodMolecular determinants of glioma cell migration and invasion
Wild-Bode, C., Weller, M., & Wick, W. (2001) · Journal of Neurosurgery · doi:10.3171/jns.2001.94.6.0978 · Cited by 130 · cited 2×
“…migration and adhesion in various glioma cells (Gladson and Cheresh, 1991; Friedlander et al., 1996) and inhibition of αvβ3 integrin with neutralizing antibody inhibited migration and invasion selectively in cell lines that contained a high level of integrin expression (Wild-Bode et al., 2001).”
Background
Cited by
The p53 Pathway in Glioblastoma
Zhang, Y., Dube, C., Gibert, M., Cruickshanks, N., Wang, B., Coughlan, M., Yang, Y., Setiady, I., Deveau, C., Saoud, K., et al. (2018) · Cancers · doi:10.3390/cancers10090297 · Cited by 440
Lan, Y., Lou, J., Hu, J., Yu, Z., Lyu, W., & Zhang, B. (2020) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2019.0164 · Cited by 46
Djuzenova, C. S., Fiedler, V., Memmel, S., Katzer, A., Hartmann, S., Krohne, G., Zimmermann, H., Scholz, C.-J., Polat, B., Flentje, M., et al. (2015) · Experimental Cell Research · doi:10.1016/j.yexcr.2014.08.013 · Cited by 34
Metadata
- Authors
- Martin, S., Janouskova, H., & Dontenwill, M.
- Venue
- Frontiers in Oncology
- Publisher
- Frontiers Media SA
- Published
- 2012
- Volume
- 2
- Pages
- 157-157
- ISSN
- 2234-943X (ISSN-L)
- OpenAlex
- W1978232668
- Cited by
- 44
- References
- 9
- FWCI
- 1.39
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.